CSL -2.5%: News overnight that CSL is apparently in talks to buy Swiss-based drug maker Vifor Pharma saw shares lower today. It’s a big deal ($8.6bn) and while CSL made the customary update to the ASX today, saying that it “regularly assesses strategic opportunities” and there was no certainty that any transaction would result from the consideration of such opportunities and does not intend to comment beyond its continuous disclosure obligations….but where there is smoke there is often fire. Watch this space.
MM is long CSL in our Flagship Growth Portfolio
Add To Hit List
